NGS Molecular Analysis & CAP-Accredited Genomic Tie-ups

Modern cancer therapy has transitioned from organ-based treatment to genomic-driven precision medicine. Every tumor possesses a distinctive genetic fingerprint of DNA mutations, gene fusions, and RNA alterations. At PCRI, we bring cutting-edge Next Generation Sequencing (NGS) and molecular oncology to our patients through strategic tie-ups with CAP (College of American Pathologists) accredited and NABL-certified genomic laboratories.

This molecular insight empowers our oncologists — Dr. Anshul Agrawal and Dr. Dhruv Mehta — to pinpoint the exact biological drivers of a patient's malignancy and select targeted therapies or immunotherapies specifically designed to neutralize those alterations.

CAP-Accredited International Quality

CAP accreditation represents the international gold standard in laboratory medicine, assuring the highest levels of accuracy, reproducibility, and clinical validation across all genomic assays.

Comprehensive Genomic Profiling (CGP) & NGS Panels

Comprehensive Solid Tumor NGS Panels: Simultaneous sequencing of hundreds of cancer-related genes, identifying actionable alterations in EGFR, ALK, ROS1, KRAS, NRAS, BRAF, HER2, BRCA1/2, PIK3CA, MET, RET, and NTRK fusions across lung, breast, colorectal, ovarian, and gastrointestinal cancers.
Liquid Biopsy (Circulating Tumor ctDNA): Non-invasive blood-based genomic profiling ideal for patients where repeat tissue biopsies are medically hazardous or unfeasible, as well as for tracking treatment resistance mutations over time.
Hematological NGS Panels: Deep genetic characterization of myeloid and lymphoid malignancies to guide risk stratification, minimal residual disease (MRD) monitoring, and targeted therapy selection.
Immunotherapy Biomarkers: Comprehensive assessment of Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI-H / dMMR) to accurately predict response to immune checkpoint inhibitors.
Hereditary Cancer Genetic Risk Panels: Germline testing for familial cancer syndromes (such as hereditary breast and ovarian cancer, Lynch syndrome) aiding preventive strategies for at-risk family members.

Molecular Tumor Board Review

Genomic data is only as valuable as its clinical interpretation. At PCRI, complex NGS reports are evaluated through a multidisciplinary lens, correlating genetic findings with clinical evidence, NCCN guidelines, and global ongoing clinical trials to design the most effective personalized treatment blueprint.